Log in

NASDAQ:SBBPStrongbridge Biopharma Stock Price, Forecast & News

$1.93
+0.19 (+10.92 %)
(As of 04/7/2020 07:36 AM ET)
Add
Compare
Today's Range
$1.85
Now: $1.93
$1.97
50-Day Range
$1.57
MA: $2.40
$3.51
52-Week Range
$1.43
Now: $1.93
$4.99
Volume339,836 shs
Average Volume316,372 shs
Market Capitalization$104.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Read More
Strongbridge Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.71 million
Book Value$1.33 per share

Profitability

Net Income$-49,450,000.00
Net Margins-227.76%

Miscellaneous

Employees106
Market Cap$104.70 million
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.


Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

How has Strongbridge Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SBBP stock has decreased by 16.8% and is now trading at $1.93. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Strongbridge Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Strongbridge Biopharma.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Strongbridge Biopharma.

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its earnings results on Tuesday, February, 25th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. The biotechnology company had revenue of $5.61 million for the quarter, compared to the consensus estimate of $4.98 million. Strongbridge Biopharma had a negative return on equity of 58.16% and a negative net margin of 227.76%. View Strongbridge Biopharma's earnings history.

What price target have analysts set for SBBP?

5 analysts have issued twelve-month price objectives for Strongbridge Biopharma's stock. Their forecasts range from $6.00 to $18.00. On average, they anticipate Strongbridge Biopharma's share price to reach $9.88 in the next twelve months. This suggests a possible upside of 411.7% from the stock's current price. View analysts' price targets for Strongbridge Biopharma.

Has Strongbridge Biopharma been receiving favorable news coverage?

Media coverage about SBBP stock has been trending very negative recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a news impact score of -3.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutStrongbridge Biopharma.

Are investors shorting Strongbridge Biopharma?

Strongbridge Biopharma saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 485,500 shares, an increase of 39.9% from the February 27th total of 347,000 shares. Based on an average trading volume of 403,700 shares, the short-interest ratio is presently 1.2 days. Approximately 1.4% of the company's stock are short sold. View Strongbridge Biopharma's Current Options Chain.

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:
  • Mr. Matthew Pauls, CEO, Pres & Director (Age 48)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 52)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 54)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $1.93.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $104.70 million and generates $21.71 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe. View additional information about Strongbridge Biopharma.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: Buy Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel